Mark Till

1.2k total citations
12 papers, 991 citations indexed

About

Mark Till is a scholar working on Immunology, Biotechnology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark Till has authored 12 papers receiving a total of 991 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 8 papers in Biotechnology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark Till's work include Toxin Mechanisms and Immunotoxins (10 papers), Transgenic Plants and Applications (8 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Mark Till is often cited by papers focused on Toxin Mechanisms and Immunotoxins (10 papers), Transgenic Plants and Applications (8 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Mark Till collaborates with scholars based in United States and United Kingdom. Mark Till's co-authors include Richard May, Ellen S. Vitetta, Jonathan W. Uhr, R J Fulton, Victor Gheţie, P L Amlot, J W Uhr, Joseph T. Newman, P. Clark and JW Fay and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and International Journal of Cancer.

In The Last Decade

Mark Till

12 papers receiving 929 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Till United States	10	747	455	385	339	115	12	991
Steven L. Giardina United States	14	372 0.5×	144 0.3×	207 0.5×	367 1.1×	181 1.6×	16	810
Cristina Musselli United States	17	786 1.1×	72 0.2×	391 1.0×	776 2.3×	243 2.1×	31	1.4k
Sandra H. Bridges United States	14	451 0.6×	42 0.1×	237 0.6×	262 0.8×	91 0.8×	27	790
Marianne Brüggemann United Kingdom	22	458 0.6×	106 0.2×	738 1.9×	702 2.1×	119 1.0×	42	1.1k
Clinton E. Leysath United States	16	227 0.3×	104 0.2×	124 0.3×	621 1.8×	144 1.3×	20	1.0k
Karen Silence Belgium	5	281 0.4×	61 0.1×	654 1.7×	523 1.5×	103 0.9×	6	884
Pauline Malinge Switzerland	13	277 0.4×	58 0.1×	304 0.8×	397 1.2×	146 1.3×	24	788
Bruce Babbitt United States	6	984 1.3×	29 0.1×	447 1.2×	437 1.3×	88 0.8×	11	1.3k
M C Nussenzweig United States	9	1.7k 2.2×	32 0.1×	358 0.9×	419 1.2×	148 1.3×	10	1.9k
Michele Pigeon United States	6	1.5k 2.0×	48 0.1×	556 1.4×	302 0.9×	315 2.7×	8	1.7k

Countries citing papers authored by Mark Till

Since Specialization

Citations

This map shows the geographic impact of Mark Till's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Till with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Till more than expected).

Fields of papers citing papers by Mark Till

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Till. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Till. The network helps show where Mark Till may publish in the future.

Co-authorship network of co-authors of Mark Till

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Till. A scholar is included among the top collaborators of Mark Till based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Till. Mark Till is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Vitetta, E S, Marvin J. Stone, P L Amlot, et al.. (1991). Phase I immunotoxin trial in patients with B-cell lymphoma.. PubMed. 51(15). 4052–8. 242 indexed citations

Gheţie, Victor, Mark Till, Thomas J. Tucker, et al.. (1990). Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin A chain using different cross-linkers. Bioconjugate Chemistry. 1(1). 24–31. 20 indexed citations

Gheţie, Victor, Mark Till, Maria-Ana Ghetie, J W Uhr, & E S Vitetta. (1990). Large scale preparation of an immunoconjugate constructed with human recombinant CD4 and deglycosylated ricin A chain. Journal of Immunological Methods. 126(1). 135–141. 9 indexed citations

Till, Mark, Victor Gheţie, Richard May, et al.. (1990). Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function.. PubMed. 3(6). 609–14. 18 indexed citations

Ghetie, Maria-Ana, Richard May, Mark Till, et al.. (1989). The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. Cellular Immunology. 118(1). 85–99. 32 indexed citations

Till, Mark, Susan Zolla‐Pazner, Miroslaw K. Górny, et al.. (1989). Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain.. Proceedings of the National Academy of Sciences. 86(6). 1987–1991. 53 indexed citations

Uhr, J W, R J Fulton, Mark Till, Richard May, & Ellen S. Vitetta. (1989). Monoclonal antibodies as carriers of toxins.. PubMed. 288. 403–12. 3 indexed citations

Shen, Guo‐Liang, Jialing Li, Maria‐Ana Ghetie, et al.. (1988). Evaluation of four CD22 antibodies as ricin a chain‐containing immunotoxins for the in vivo therapy of human B‐cell leukemias and lymphomas. International Journal of Cancer. 42(5). 792–797. 64 indexed citations

Till, Mark, Victor Gheţie, Timothy J. Gregory, et al.. (1988). HIV-Infected Cells Are Killed by rCD4-Ricin A Chain. Science. 242(4882). 1166–1168. 123 indexed citations

10.

Ghetie, Maria‐Ana, Richard May, Mark Till, et al.. (1988). Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.. PubMed. 48(9). 2610–7. 107 indexed citations

11.

Till, Mark, Richard May, Jonathan W. Uhr, Philip E. Thorpe, & Ellen S. Vitetta. (1988). An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins.. PubMed. 48(5). 1119–23. 39 indexed citations

12.

Vitetta, Ellen S., R J Fulton, Richard May, Mark Till, & Jonathan W. Uhr. (1987). Redesigning Nature's Poisons to Create Anti-Tumor Reagents. Science. 238(4830). 1098–1104. 281 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact